Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Epidemiological and clinical aspects of Polyomaviridae infections – a literature review
1
Students’ Scientific Club at the Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
2
Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
Corresponding author
Anna Kozub
Students’ Scientific Club at the Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
Students’ Scientific Club at the Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
Ann. Acad. Med. Siles. 2024;2(nr specj.):12-19
KEYWORDS
TOPICS
SurgeryInfectious DiseasesLaboratory DiagnosticsEpidemiologyImmunologyCardiosurgeryMicrobiologyOncology
ABSTRACT
Polyomaviridae (PyV) are small, non-enveloped viruses leading after infection to mainly asymptomatic or oligosymptomatic disorders among different vertebrates. Currently 14 PyV are known to affect human health. This literature review aims to summarise accessible knowledge from both epidemiological and clinical studies conducted on healthy and PyV infected human populations, with a focus on studies containing transplantation and oncology issues. The search strategy involved screening four databases and finally 25 studies were selected for this article. The majority of the studies focused on the influence of BKPyV and JCPyV infections on renal graft recipients. Some research also described the prevalence of MCPyV and future oncological treatment. The results revealed that various types of patient fluids and tissues may be useful in PyV detection. Moreover, heterogeneity in available evidence on each PyV is observed. The studies implied possible future directions for PyV studies, including new biomarkers, the examination of risk factors or comparison of the course of the disease and treatment results in various age groups of patients.
CONFLICT OF INTEREST
None declared.
REFERENCES (35)
1.
Calvignac-Spencer S., Feltkamp M.C.W., Daugherty M.D., Moens U., Ramqvist T., Johne R. et al. A taxonomy update for the family Polyomaviridae. Arch. Virol. 2016; 161(6): 1739–1750, doi: 10.1007/s00705-016-2794-y.
2.
Gottlieb K.A., Villarreal L.P. Natural biology of polyomavirus middle T antigen. Microbiol. Mol. Biol. Rev. 2001; 65(2): 288–318, doi: 10.1128/MMBR.65.2.288-318.2001.
3.
Gross L. A filterable agent, recovered from Ak leukemic extracts, causing salivary gland carcinomas in C3H mice. Proc. Soc. Exp. Biol. Med. 1953; 83(2): 414–421, doi: 10.3181/00379727-83-20376.
4.
Eddy B.E., Stewart S.E. Characteristics of the SE polyoma virus. Am. J. Public Health Nations Health 1959; 49(11): 1486–1492, doi: 10.2105/ajph.49.11.1486.
5.
Gossai A., Waterboer T., Nelson H.H., Michel A., Willhauck-Fleckenstein M., Farzan S.F. et al. Seroepidemiology of human polyomaviruses in a US population. Am. J. Epidemiol. 2016; 183(1): 61–69, doi: 10.1093/aje/kwv155.
6.
Kitamura T., Kunitake T., Guo J., Tominaga T., Kawabe K., Yogo Y. Transmission of the human polyomavirus JC virus occurs both within the family and outside the family. J. Clin. Microbiol. 1994; 32(10): 2359–2363, doi: 10.1128/jcm.32.10.2359-2363.1994.
7.
Ahsan N., Shah K.V. Polyomaviruses and human diseases. Adv. Exp. Med. Biol. 2006; 577: 1–18, doi: 10.1007/0-387-32957-9_1.
8.
Fluck M.M., Schaffhausen B.S. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol. Mol. Biol. Rev. 2009; 73(3): 542–563, doi: 10.1128/MMBR.00009-09.
9.
Ehlers B., Anoh A.E., Salem N.B., Broll S., Couacy-Hymann E., Fischer D. et al. Novel polyomaviruses in mammals from multiple orders and reassessment of polyomavirus evolution and taxonomy. Viruses 2019; 11(10): 930, doi: 10.3390/v11100930.
10.
López V., Gutiérrez C., Burgos D., González Molina M., Cabello M., Sola E. et al. Prospective study of infection and nephropathy due to BK and JC polyomavirus in 76 kidney transplant recipients. Transplant. Proc. 2008; 40(9): 2927–2929, doi: 10.1016/j.transproceed.2008.08.098.
11.
Schwarz A., Linnenweber-Held S., Heim A., Framke T., Haller H., Schmitt C. Viral origin, clinical course, and renal outcomes in patients with BK virus infection after living-donor renal transplantation. Transplantation 2016; 100(4): 844–853, doi: 10.1097/TP.0000000000001066.
12.
Egli A., Infanti L., Dumoulin A., Buser A., Samaridis J., Stebler C. et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis. 2009; 199(6): 837–846, doi: 10.1086/597126.
13.
Silling S., Kreuter A., Gambichler T., Meyer T., Stockfleth E., Wieland U. Epidemiology of Merkel cell polyomavirus infection and Merkel cell carcinoma. Cancers (Basel) 2022; 14(24): 6176, doi: 10.3390/cancers14246176.
14.
Dehcheshmeh L.K., Makvandi M., Timori A. Prevalence of human polyomavirus JC and BK in normal population. Asian Pac. J. Cancer Prev. 2020; 21(10): 2877–2882, doi: 10.31557/APJCP.2020.21.10.2877.
15.
Mertz K.D., Paasinen A., Arnold A., Baumann M., Offner F., Willi N. et al. Merkel cell polyomavirus large T antigen is detected in rare cases of nonmelanoma skin cancer. J. Cutan. Pathol. 2013; 40(6): 543–549, doi: 10.1111/cup.12129.
16.
Gossai A., Waterboer T., Nelson H.H., Doherty J.A., Michel A., Willhauck-Fleckenstein M. et al. Prospective study of human polyomaviruses and risk of cutaneous squamous cell carcinoma in the United States. Cancer Epidemiol. Biomarkers Prev. 2016; 25(5): 736–744, doi: 10.1158/1055-9965.EPI-15-1111.
17.
Mogha A., Fautrel A., Mouchet N., Guo N., Corre S., Adamski H. et al. Merkel cell polyomavirus small T antigen mRNA level is increased following in vivo UV-radiation. PLoS One 2010; 5(7): e11423, doi: 10.1371/journal.pone.0011423.
18.
Gardner S.D., MacKenzie E.F., Smith C., Porter A.A. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J. Clin. Pathol. 1984; 37(5): 578–586, doi: 10.1136/jcp.37.5.578.
19.
Mengelle C., Kamar N., Mansuy J.M., Sandres-Sauné K., Legrand-Abravanel F., Miédougé M. et al. JC virus DNA in the peripheral blood of renal transplant patients: a 1-year prospective follow-up in France. J. Med. Virol. 2011; 83(1): 132–136, doi: 10.1002/jmv.21951.
20.
Dolci M., Colico C., Ambrogi F., Favi E., Signorini L., Perego M. et al. Longitudinal study of human polyomaviruses viruria in kidney transplant recipients. Clin. Exp. Med. 2024; 24(1): 3, doi: 10.1007/s10238-023-01290-z.
21.
Chan B.D., Wong G., Jiang Q., Lee M.M.L., Wong W.Y., Chen F. et al. Longitudinal study of BK Polyomavirus outcomes, risk factors, and kinetics in renal transplantation patients. Microb. Pathog. 2020; 142: 104036, doi: 10.1016/j.micpath.2020.104036.
22.
Costa J.S., Ferreira E., Leal R., Bota N., Romãozinho C., Sousa V. et al. Polyomavirus nephropathy: ten-year experience. Transplant. Proc. 2017; 49(4): 803–808, doi: 10.1016/j.transproceed.2017.01.072.
23.
Huang G., Chen L.Z., Qiu J., Wang C.X., Fei J.G., Deng S.X. et al. Prospective study of polyomavirus BK replication and nephropathy in renal transplant recipients in China: a single-center analysis of incidence, reduction in immunosuppression and clinical course. Clin. Transplant. 2010; 24(5): 599–609, doi: 10.1111/j.1399-0012.2009.01141.x.
24.
Soleymanian T., Keyvani H., Jazayeri S.M., Fazeli Z., Ghamari S., Mahabadi M. et al. Prospective study of BK virus infection and nephropathy during the first year after kidney transplantation. Iran. J. Kidney Dis. 2014; 8(2): 145–151.
25.
Kamminga S., van Rijn A.L., de Brouwer C.S., Rotmans J.I., Zaaijer H.L., Feltkamp M.C.W. JC and human polyomavirus 9 after kidney transplantation: An exploratory serological cohort study. J. Clin. Virol. 2021; 143: 104944, doi: 10.1016/j.jcv.2021.104944.
26.
Bialasiewicz S., Rockett R.J., Barraclough K.A., Leary D., Dudley K.J., Isbel N.M. et al. Detection of recently discovered human polyomaviruses in a longitudinal kidney transplant cohort. Am. J. Transplant. 2016; 16(9): 2734–2740, doi: 10.1111/ajt.13799.
27.
Castro T., Fink M.C.D., Figueiredo M., Braz-Silva P.H., Pannuti C.M., Ortega K.L. et al. Polyomavirus BK and JC in individuals with chronic kidney failure, kidney transplantation, and healthy controls. J. Clin. Virol. 2017; 89: 5–9, doi: 10.1016/j.jcv.2017.02.003.
28.
Fang Y., Zhang C., Wang Y., Yu Z., Wu Z., Zhou Y. et al. Dynamic risk prediction of BK polyomavirus reactivation after renal transplantation. Front. Immunol. 2022; 13: 971531, doi: 10.3389/fimmu.2022.971531.
29.
Ducharme-Smith A., Katz B.Z., Bobrowski A.E., Backer C.L., Pahl E. BK polyomavirus infection in pediatric heart transplant recipients: a prospective study. Pediatr. Transplant. 2017; 21(2), doi: 10.1111/petr.12830.
30.
Feng H., Shuda M., Chang Y., Moore P.S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319(5866): 1096–1100, doi: 10.1126/science.1152586.
31.
Nghiem P.T., Bhatia S., Lipson E.J., Kudchadkar R.R., Miller N.J., Annamalai L. et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N. Engl. J. Med. 2016; 374(26): 2542–2552, doi: 10.1056/NEJMoa1603702.
32.
Nghiem P., Bhatia S., Lipson E.J., Sharfman W.H., Kudchadkar R.R., Brohl A.S. et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J. Clin. Oncol. 2019; 37(9): 693–702, doi: 10.1200/JCO.18.01896.
33.
Kaufman H.L., Russell J.S., Hamid O., Bhatia S., Terheyden P., D’Angelo S.P. et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J. Immunother. Cancer 2018; 6(1): 7, doi: 10.1186/s40425-017-0310-x.
34.
D’Angelo S.P., Lebbé C., Mortier L., Brohl A.S., Fazio N., Grob J.J. et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J. Immunother. Cancer 2021; 9(7): e002646, doi: 10.1136/jitc-2021-002646.
35.
Topalian S.L., Bhatia S., Amin A., Kudchadkar R.R., Sharfman W.H., Lebbé C. et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 Trial. J. Clin. Oncol. 2020; 38(22): 2476–2487, doi: 10.1200/JCO.20.00201.
Share
RELATED ARTICLE
| eISSN: | 1734-025X |
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
